Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

If you have diabetes, taking steps to manage it can help prevent related health issues, including MASH. Here’s what to know ...

Weight-loss surgery lowers risk of developing complications of liver disease in patients with cirrhosis and obesity Bariatric surgery favorably influences progression of cirrhosis Date: January 27 ...

In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other stocks. Wall Street’s main indices kicked off the trading week soaring on Tuesday amid ...

TEM shares currently trade at a significant premium at 8.64x price/sales on a trailing twelve-month basis. This compares to the peer cohort average of 3.05x. Despite this factor, Tempus is ...

See Also: US Stocks Set To Open On A Positive Note As Trump’s Second White House Term Kicks Off: Tesla, Apple, Netflix Among Stocks In Focus TEM Price Action: Tempus AI shares were up 18.0% at $ ...